Business
Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients
Press Release Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients Achieving the primary endpoint in both Denali and the first NCX 470 Phase 3 trial, Mont Blanc, meets efficacy requirements for approval in the U.S. and ChinaNCX 470 was also superior to latanoprost in the reduction of intraocular pressure (IOP) from baseline (p<0.05) at 3 out of 6 timepoints and numerically greater at 5 out of 6 timepointsNCX 470 0.1% was safe and well tolerated New Drug App
About this update from Nicox Sa
[{"type":"image","alt":"NICOX SA","displaySize":"","headline":null,"caption":"NICOX SA","className":"","disableSlideshowImg":false,"size":{"original":{"width":290,"height":177,"url":"https://media.zenfs.com/en/globenewswire.com/e5c6c949c0184e4a40b35f1bde81d2f8"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/rPuxYymeI_hpr5ShJmv9pw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI1NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e5c6c949c0184e4a40b35f1bde81d2f8","width":290,"height":177}},"lazy":false},{"type":"table","headerItems":[],"items":[{"val":[{"colspan":"2","style":"width:623.67px;border-bottom:solid black 1pt;vertical-align:top;","val":[{"type":"text","content":"Press Release ","length":13,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"2","style":"width:623.67px;border-top:solid black 1pt;border-bottom:solid black 1pt;text-align:justify;vertical-align:middle;vertical-align:top;","val":[{"type":"text","content":"Nicox Announces Positive Results from the NCX 470 Phase 3 Denali Trial in Glaucoma Patients","length":91,"tagName":"p","attribs":{}}]}]},{"val":[{"colspan":"2","style":"width:623.67px;vertical-align:top;","val":[{"type":"list","items":[{"val":[{"type":"text","content":"Achieving the primary endpoint in both Denali and the first NCX 470 Phase 3 trial, Mont Blanc, meets efficacy requirements for approval in the U.S. and China","length":157,"tagName":"p"}]},{"val":[{"type":"text","content":"NCX 470 was also superior to latanoprost in the reduction of intraocular pressure (IOP) from baseline (p<0.05) at 3 out of 6 timepoints and numerically greater at 5 out of 6 timepoints","length":187,"tagName":"p"}]},{"val":[{"type":"text","content":"NCX 470 0.1% was safe and well tolerated ","length":40,"tagName":"p"}]},{"val":[{"type":"text","content":"New Drug Application (NDA) submission in the U.S. currently expected in H1 2026 ","length":79,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":463,"olType":false},{"type":"text","content":"August 21, 2025 – release at 7:30 am CETSophia Antipolis, FranceNicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that once daily dosing of NCX 470 0.1%, a novel nitric oxide (NO)-donating bimatoprost eye drop, met the primary objective of non-inferiority in lowering intraocular pressure (IOP) from baseline compared to the standard of care...